Development Programs > Preclinical Development Programs > Hepatitis C Therapy

Hepatitis C Therapy

Our hepatitis C (HCV) therapeutic product candidate utilizes a novel ISS, called a Type C TLR9 agonist, and is designed to induce a strong T-cell immune response, increase interferon production and provide longer-lasting antiviral effects. By combining these different mechanisms, we believe our HCV therapy will be able to stop viral replication and induce a long-lasting immune response, thereby improving on currently available interventions. One potential use of our approach would to administer it in combination with orally available antiviral compounds.

Our hepatitis C preclinical program is being funded by Symphony Dynamo, Inc. (SDI). In April 2006, SDI committed $50 million to Dynavax to advance its cancer program, along with its therapies for chronic hepatitis B and hepatitis C, into clinical trials.